Health
New study from MD Anderson and BridgeBio’s Navire Pharma shows SHP2 inhibition overcomes multiple – Mirage News
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the…
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell lung cancer (NSCLC), suggesting a possible new approach to treating cancers that have developed resistance to the targeted EGFR inhibitor osimertinib.
The data is published today in Cancer Research, a journal of the American Associat…
-
Noosa News21 hours agoHow Lily Steele-Park took her rapist to court and won
-
Business24 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025
-
Noosa News22 hours agoE-biker charged with riding dangerously, assaulting cop
-
General20 hours agoBrick portico a relic of ‘prestigious’ Horton College in northern midlands